Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake
- 10 May 2016
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 47 (3) , 185-193
Abstract
1. The plasma clearance of the first-in-class DOT1L inhibitor, EPZ-5676 (pinometostat), was shown to be markedly lower in human compared to the preclinical species, mouse, rat and dog. 2. This led to vertical allometry where various interspecies scaling methods were applied to the data, with fold-errors between 4 and 13. We had previously reported the elimination and metabolic pathways of EPZ-5676 were similar across species. Therefore, the aim of this work was to explore the mechanistic basis for the species difference in clearance for EPZ-5676, focusing on other aspects of disposition. 3. The protein binding of EPZ-5676 in human plasma demonstrated a non-linear relationship suggesting saturable binding at physiologically relevant concentrations. Saturation of protein binding was not observed in plasma from preclinical species. Kinetic determinations using purified serum albumin and alpha-1-acid glycoprotein (AAG) confirmed that EPZ-5676 is a high affinity ligand for AAG with a dissociation constant (Kd) of 0.24 μM. 4. Permeability limited uptake was also considered since hepatocyte CLint was much lower in human relative to preclinical species. Passive unbound CLint for EPZ-5676 was estimated using a correlation analysis of logD and data previously reported on seven drugs in sandwich cultured human hepatocytes. 5. Incorporation of AAG binding and permeability limited hepatic uptake into the well-stirred liver model gave rise to a predicted clearance for EPZ-5676 within 2-fold of the observed value of 1.4 mL min−1 kg−1. This analysis suggests that the marked species difference in EPZ-5676 clearance is driven by high affinity binding to human AAG as well as species-specific hepatic uptake invoking the role of transporters.Keywords
This publication has 45 references indexed in Scilit:
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaBlood, 2013
- Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsBritish Journal of Clinical Pharmacology, 2012
- Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexesProceedings of the National Academy of Sciences, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- Identification, Characterization, and Implications of Species-Dependent Plasma Protein Binding for the Oral Hedgehog Pathway Inhibitor Vismodegib (GDC-0449)Journal of Medicinal Chemistry, 2011
- RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapiesArthritis Research & Therapy, 2009
- Dog alpha-1-acid glycoprotein: Purification and biochemical characterizationJournal of Pharmacological Methods, 2002
- Alpha-1-acid glycoproteinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Measurement and Analysis of Unbound Drug ConcentrationsClinical Pharmacokinetics, 1996
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982